Trium Capital LLP Makes New Investment in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Trium Capital LLP acquired a new stake in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 386,407 shares of the company’s stock, valued at approximately $3,710,000. Poseida Therapeutics comprises 0.5% of Trium Capital LLP’s investment portfolio, making the stock its 7th biggest position.

Several other hedge funds and other institutional investors have also recently modified their holdings of PSTX. Renaissance Technologies LLC increased its holdings in Poseida Therapeutics by 53.4% in the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after acquiring an additional 297,500 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Poseida Therapeutics by 62.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock worth $1,027,000 after purchasing an additional 138,510 shares in the last quarter. Blair William & Co. IL increased its stake in shares of Poseida Therapeutics by 14.1% in the second quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock worth $3,216,000 after purchasing an additional 136,273 shares in the last quarter. Fred Alger Management LLC bought a new stake in shares of Poseida Therapeutics during the 3rd quarter valued at $369,000. Finally, Advantage Alpha Capital Partners LP purchased a new position in shares of Poseida Therapeutics during the 3rd quarter valued at $285,000. 46.87% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Poseida Therapeutics

In related news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total transaction of $283,800.00. Following the sale, the chairman now owns 651,291 shares of the company’s stock, valued at $6,161,212.86. This represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.90% of the stock is currently owned by company insiders.

Poseida Therapeutics Stock Performance

Shares of PSTX stock opened at $9.50 on Friday. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $928.85 million, a price-to-earnings ratio of -15.08 and a beta of 1.63. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.67. The stock’s 50-day moving average price is $8.04 and its 200-day moving average price is $4.70.

Wall Street Analyst Weigh In

PSTX has been the subject of a number of analyst reports. BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Cantor Fitzgerald cut Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Finally, Piper Sandler cut shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a research report on Monday, December 2nd. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.50.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.